AI-guided natural-product-inspired molecules inhibit two multidrug-resistance transporters
Combining marine natural-product fragment mining, AI-based molecular generation and structure-guided selection, the authors designed optimized analogues Ib18 and It12 targeting the ABC transporters P-glycoprotein (ABCB1) and BCRP (ABCG2). Both analogues reversed transporter-mediated resistance in overexpressing cells and outperformed reference inhibitors. Target-engagement assays supported transporter inhibition without expression downregulation. In xenografts, Ib18 increased mitoxantrone antitumor activity and tumor accumulation without a detected increase in systemic toxicity.
Technology: AI-based molecular generation integrated with marine natural-product fragment mining and structure-guided prioritization
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Target-engagement assays supported transporter inhibition without expression downregulation.
- Still unknown: The evidence is cellular and preclinical xenograft evidence, not patient efficacy or established clinical safety. The abstract reports no systemic toxicity increase in the studied xenograft setting, which should not be generalized. It does not give quantitative potency values or detailed comparator identities in the abstract.
- AI role: AI-based generation contributed candidates to a natural-product-inspired library; structure-guided prioritization selected optimized analogues for synthesis and functional tests. The authors tested Ib18 and It12 in transporter-overexpressing cells and evaluated Ib18 with mitoxantrone in xenografts.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/42720471/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.